businesspress24.com - CEOLIVE.TV Announces New Interview With Gregg Gellman, Director of Business Development for 22nd Cen
 

CEOLIVE.TV Announces New Interview With Gregg Gellman, Director of Business Development for 22nd Century Group, Inc.

ID: 1433273

(firmenpresse) - ORLANDO, FL -- (Marketwired) -- 05/06/16 -- CEOLIVE, Inc., A provider of in-depth video interviews with public company CEO''s (), announced today that a new interview with Gregg Gellman, Director of Business Development and Regulatory Affairs for 22nd Century Group (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction is now available on their website.

The video interview can be viewed at the following link:





22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company''s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. Learn more at .



This CEOLIVE.TV video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company''s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company''s contracts, the Company''s ability to raise sufficient development and working capital, the Company''s liquidity position, the Company''s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.



CEOLIVE content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOLIVE content and productions, or other investor relations materials and presentations are subject to change. Neither CEOLIVE nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. CEOLIVE is not a registered broker-dealer or registered investment advisor.







Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Theravance Biopharma Announces New Employment Inducement Awards
Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis
Bereitgestellt von Benutzer: Marketwired
Datum: 06.05.2016 - 10:30 Uhr
Sprache: Deutsch
News-ID 1433273
Anzahl Zeichen: 5302

contact information:
Contact person:
Town:

ORLANDO, FL


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 384 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"CEOLIVE.TV Announces New Interview With Gregg Gellman, Director of Business Development for 22nd Century Group, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von

CEOLIVE.TV (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von CEOLIVE.TV



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 79


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.